EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
21st Annual PEGS Boston Summit – Presentation
The Citizens Life Sciences Conference – Presentation
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., May 1, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that management will participate in two upcoming...
2025 American Association for Cancer Research (AACR) Annual Meeting – Poster Presentations
Title: Preclinical activity and safety of STRO-004, a novel ADC targeting tissue factor for solid tumors Abstract: #1572 Session: PO.ET02.01 - Antibody-Based Cancer Therapeutics 1 Date & Time: Monday, April 28, 2025, 9:00 a.m. - 12:00 p.m. CTPresenter: Alice Yam,...
Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025
- Preclinical findings show STRO-004's promising anti-tumor activity and favorable safety profile - SOUTH SAN FRANCISCO, Calif., April 28, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), an oncology company pioneering site-specific and novel-format...
Society Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer – Presentation
Sutro Biopharma Presents Data from Dose-Optimization Portion of REFRαME-O1 Trial in Patients with Platinum Resistant Ovarian Cancer at SGO 2025
- The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater - SOUTH SAN FRANCISCO, Calif., March 15, 2025 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:...
Sutro Biopharma, Inc. Conference Call – Presentation
Sutro Biopharma Announces Strategic Portfolio Review Resulting in the Prioritization of its Next-Generation ADC Pipeline
– Sutro will rapidly advance next-generation exatecan and dual-payload ADC programs; luveltamab tazevibulin development to be deprioritized as Sutro continues to seek a partner – – Three INDs for wholly-owned programs expected in the next 3 years, beginning with novel...